Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications - Seite 2

Julien Valton, Ph.D., Innovation Team Leader, Cellular Engineering & Adoptive CAR T-Cell Immunotherapy

Dr. Julien Valton obtained his Ph.D. at the University Joseph Fourier in Grenoble, France, where he was trained as an enzymologist. He then joined the Yale School of Medicine to apply his knowledge to therapeutic research by investigating the mechanism of inhibition of receptor tyrosine kinases that are involved in the development of gastrointestinal cancer. In 2009, he moved a step further into the field of applied science by joining the Innovation Department of Cellectis, where he actively participated in using and improving TALEN gene editing technology for targeted gene therapy and genome engineering. He is now using TALEN along with protein engineering techniques to develop the next-generation CAR T-cells to treat different malignancies.

Repurposing Endogenous Immune Pathways to Tailor and Control Chimeric Antigen Receptor T-cell Functionality

Mohit Sachdeva¹, Brian W. Busser¹, Sonal Temburni¹, Billal Jahangiri¹, Anne-Sophie Gautron², Alan Maréchal², Alexandre Juillerat¹, Alan Williams¹, Stéphane Depil², Philippe Duchateau², Laurent Poirot² and Julien Valton¹

¹Cellectis, Inc., 430 East 29th Street, New York, NY 10016, USA
²Cellectis, 8 rue de la Croix Jarry, 75013 Paris, France

About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T therapies, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR-T cells to treat patients. As a clinical-stage biopharmaceutical company with over 19 years of expertise in gene editing, we are developing game-changer product candidates in immune-oncology. Utilizing TALEN, our proprietary gene editing technology, and PulseAgile, our pioneering electroporation system, we are harnessing the power of the immune system to target and eradicate cancer cells.

As part of our commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet need for multiple cancers including B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Cellectis is listed on the Nasdaq (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. For more information, visit www.cellectis.com.

Follow Cellectis on social media: @Cellectis, LinkedIn and YouTube.